Clinical evaluation of two novel biointact PTH(1-84) assays in hemodialysis patients

Clinical Biochemistry

Volumn 45, Issue 18, 2012, Pages 1645-1651

  Hecking, Manfred ^a   Kainz, Alexander ^a   Bielesz, Bernhard ^a   Plischke, Max ^a   Beilhack, Georg ^a   Hörl, Walter H ^a   Sunder Plassmann, Gere ^a   Bieglmayer, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Automated biointact; Chronic kidney disease mineral and bone disorder (CKD MBD); Hemodialysis patients; Parathyroid hormone (PTH); PTH(1 84) assays

Indexed keywords

CREATININE; PARATHYROID HORMONE; PHOSPHATE;

ADULT; ANALYZER; ARTICLE; BIOINTACT PARATHYROID HORMONE ASSAY; BONE DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CREATININE BLOOD LEVEL; FEMALE; HEMODIALYSIS; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL;

BIOLOGICAL ASSAY; CREATININE; DEMOGRAPHY; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; RENAL DIALYSIS;

EID: 84870725414     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.08.006     Document Type: Article

References (42)

1. Souberbielle J.C., Roth H., Fouque D.P. Parathyroid hormone measurement in CKD. Kidney Int 2010, 77:93-100.
2. KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease 2009.
3. Juppner H. Phosphate and FGF-23. Kidney Int Suppl 2011, S24-S27.
4. Kawata T., Imanishi Y., Kobayashi K., Miki T., Arnold A., Inaba M., et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007, 18:2683-2688.
5. Krajisnik T., Bjorklund P., Marsell R., Ljunggren O., Akerstrom G., Jonsson K.B., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007, 195:125-131.
6. Gutierrez O., Isakova T., Rhee E., Shah A., Holmes J., Collerone G., et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005, 16:2205-2215.
7. Larsson T.E. The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe?. Nephrol Dial Transplant 2010, 25:1376-1381.
8. Brancaccio D., Di Leo C., Bestetti A., Carpani P., Tagliabue L., Cozzolino M., et al. Severe cortical and trabecular osteopenia in secondary hyperparathyroidism. Hemodial Int 2003, 7:122-129.
9. Jamal S.A., Gilbert J., Gordon C., Bauer D.C. Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res 2006, 21:543-548.
10. Wehrli F.W., Leonard M.B., Saha P.K., Gomberg B.R. Quantitative high-resolution magnetic resonance imaging reveals structural implications of renal osteodystrophy on trabecular and cortical bone. J Magn Reson Imaging 2004, 20:83-89.
11. Cejka D., Jager-Lansky A., Kieweg H., Weber M., Bieglmayer C., Haider D.G., et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2011.
12. Cejka D., Herberth J., Branscum A.J., Fardo D.W., Monier-Faugere M.C., Diarra D., et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011, 6:877-882.
13. Monier-Faugere M.C., Geng Z., Mawad H., Friedler R.M., Gao P., Cantor T.L., et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001, 60:1460-1468.
14. Moe S., Drueke T., Cunningham J., Goodman W., Martin K., Olgaard K., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 2006, 69:1945-1953.
15. Slatopolsky E., Finch J., Clay P., Martin D., Sicard G., Singer G., et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000, 58:753-761.
16. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009, S1-S130.
17. Matuszkiewicz-Rowinska J. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of mineral and bone disorders in chronic kidney disease. Pol Arch Med Wewn 2010, 120:300-306.
18. Brossard J.H., Cloutier M., Roy L., Lepage R., Gascon-Barre M., D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996, 81:3923-3929.
19. Brossard J.H., Lepage R., Cardinal H., Roy L., Rousseau L., Dorais C., et al. Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 2000, 46:697-703.
20. Friedman P.A., Goodman W.G. PTH(1-84)/PTH(7-84): a balance of power. Am J Physiol Renal Physiol 2006, 290:F975-F984.
21. Lepage R., Roy L., Brossard J.H., Rousseau L., Dorais C., Lazure C., et al. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998, 44:805-809.
22. Nguyen-Yamamoto L., Rousseau L., Brossard J.H., Lepage R., D'Amour P. Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 2001, 142:1386-1392.
23. Langub M.C., Monier-Faugere M.C., Wang G., Williams J.P., Koszewski N.J., Malluche H.H. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 2003, 144:1135-1138.
24. Divieti P., John M.R., Juppner H., Bringhurst F.R. Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 2002, 143:171-176.
25. Cantor T., Yang Z., Caraiani N., Ilamathi E. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem 2006, 52:1771-1776.
26. Hollis B.W. Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. Am J Clin Nutr 2008, 88:507S-510S.
27. Cantor T. Parathyroid hormone assay drift: an unappreciated problem in dialysis patient management. Semin Dial 2005, 18:359-364.
28. Gao P., Scheibel S., D'Amour P., John M.R., Rao S.D., Schmidt-Gayk H., et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001, 16:605-614.
29. Ljungdahl N., Haarhaus M., Linder C., Magnusson P. Comparison of 3 third-generation assays for bio-intact parathyroid hormone. Clin Chem 2006, 52:903-904.
30. Terry A.H., Orrock J., Meikle A.W. Comparison of two third-generation parathyroid hormone assays. Clin Chem 2003, 49:336-337.
31. Oddoze C., Lombard E., Portugal H. Stability study of 81 analytes in human whole blood, in serum and in plasma. Clin Biochem 2012, 45:464-469.
32. English E., McFarlane I., Taylor K.P., Halsall D.J. The effect of potassium EDTA on the stability of parathyroid hormone in whole blood. Ann Clin Biochem 2007, 44:297-299.
33. Bablok W., Passing H., Bender R., Schneider B. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988, 26:783-790.
34. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1:307-310.
35. Tentori F., Blayney M.J., Albert J.M., Gillespie B.W., Kerr P.G., Bommer J., et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008, 52:519-530.
36. Tentori F., Albert J.M., Young E.W., Blayney M.J., Robinson B.M., Pisoni R.L., et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the dialysis outcomes and practice patterns study. Nephrol Dial Transplant 2009, 24:963-972.
37. Tentori F, Steffick D, Pisoni RL, Gillespie BW, Kerr PG, Jacobson SH, Akiba T, Robinson BM. Cinacalcet Therapy & Mortality among Hemodialysis Patients: International Results from the DOPPS. In: Book Cinacalcet Therapy & Mortality among Hemodialysis Patients: International Results from the DOPPS (Editor ed.^eds.). City; 2011.
38. Inaba M., Okuno S., Imanishi Y., Ueda M., Yamakawa T., Ishimura E., et al. Significance of Bio-intact PTH(1-84) assay in hemodialysis patients. Osteoporos Int 2005, 16:517-525.
39. Ganesh S.K., Stack A.G., Levin N.W., Hulbert-Shearon T., Port F.K. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001, 12:2131-2138.
40. Block G.A., Klassen P.S., Lazarus J.M., Ofsthun N., Lowrie E.G., Chertow G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004, 15:2208-2218.
41. Melamed M.L., Eustace J.A., Plantinga L.C., Jaar B.G., Fink N.E., Parekh R.S., et al. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transplant 2008, 23:1650-1658.
42. Inaba M., Nakatsuka K., Imanishi Y., Watanabe M., Mamiya Y., Ishimura E., et al. Technical and clinical characterization of the Bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clin Chem 2004, 50:385-390.